A Novel MYO5A Mutation (c.3508C>T) in a 27‐Month‐Old Girl With Hypotonia and Developmental Delay: Expanding the Phenotypic Spectrum of Griscelli Syndrome Type 1 Authors: Davoud AmirKashani, Soudabeh Hosseini, Marziyeh Mojbafan, Niusha Sharifinejad, Sima Bahrami Published: 2026 ABSTRACT BackgroundGriscelli syndrome (GS) is a rare autosomal recessive disorder, characterized by pigmentary dilution of hair and skin. There are three known types of this disease. GS type 1 (GS1), due to mutations in MYO5A, is associated with neurological impairment and hypotonia, while GS type 2 (GS2; RAB27A variants) involves immune dysregulation (hemophagocytic lymphohistiocytosis [HLH]) and GS type 3 (MLPH variants) causes isolated pigmentary defects.Case PresentationWe report a 27‑month‑old Afghan girl, born to consanguineous parents, presenting with developmental delay and hypotonia without the classic silvery hair. A complete evaluation was performed to determine the cause of the developmental delay. Whole exome sequencing revealed a novel homozygous MYO5A variant (c.3508C >T), confirming GS1. Despite the absence of the characteristic silvery hair, microscopic hair examination of the patient showed melanin distribution abnormalities.ConclusionThis case highlights the phenotypical variability in GS1 and emphasizes on the importance of considering genetic testing even in atypical presentations. Exploring these novel mutations can expand the known genotype/phenotype spectrum of GS1. 1. Introduction Griscelli syndrome (GS) is a rare autosomal recessive disorder characterized by pigmentary dilution of the skin and hair. Three distinct classifications of GS have been described according to the underlying genetic defect and clinical features, all sharing pigmentary abnormalities from birth or very early infancy [1]; type 1, resulting from mutations in the MYO5A gene, is mainly associated with hypotonia and severe neurodevelopmental delay [2]. Type 2, caused by mutations in RAB27A, typically presents with immunological dysfunction and is often recognized during episodes of hemophagocytic lymphohistiocytosis (HLH) [3]. Type 3, related to variants in the MLPH gene, manifests only with pigmentary changes without neurological or immunological involvement [4]. So far, the majority of reported cases are categorized as type 2, while type 1 and 3 remain exceedingly rare. While GS type 2 (GS2) is often fatal and the only cure is hematopoietic stem cell transplantation (HSCT), the treatment for GS type 1 (GS1) is only symptomatic. There is no specific management for GS3 [1]. Table 1 provides a better understanding of the different types of GS. Table 1Clinical and genetic features of Griscelli syndrome subtypes.SubtypeGeneMain featuresOnset/time coursePrognosisGS1 MYO5A Neurological impairment, hypotonia, pigmentary abnormalitiesNeurological symptoms and pigment changes typically appear at birth or in early infancyPoor; progressive neurological declineGS2 RAB27A Immune dysfunction, HLH, pigmentary changes ‐ Pigment changes at birth or early infancy‐ Immune dysfunction appears in infancy (usually before 2 years)‐ HLH episodes often occur within the first months to first year of life Life‐threatening without HSCTGS3 MLPH Isolated pigmentary defects onlyPigment changes apparent from birth or early infancyBenignAbbreviations: GS, Griscelli syndrome; HLH, hemophagocytic lymphohistiocytosis; HSCT, hematopoietic stem cell transplantation. Clinical and genetic features of Griscelli syndrome subtypes. ‐ Pigment changes at birth or early infancy ‐ Pigment changes at birth or early infancy ‐ Immune dysfunction appears in infancy (usually before 2 years) ‐ Immune dysfunction appears in infancy (usually before 2 years) ‐ HLH episodes often occur within the first months to first year of life ‐ HLH episodes often occur within the first months to first year of life Abbreviations: GS, Griscelli syndrome; HLH, hemophagocytic lymphohistiocytosis; HSCT, hematopoietic stem cell transplantation. Here, we present an interesting case of GS1 with neurodevelopmental disorder carrying a novel MYO5A (c.3508C >T, p.Gln1170 ∗) mutation. 2. Case Presentation A 27‑month‐old Afghan girl was referred to the immunology clinic. She was the first child of consanguineous parents, born via cesarean section with normal Apgar scores. No previous family history of similar condition, miscarriage, or neonatal death was present. At the time of her first appointment, she had light brown hair, lighter than her parents, which remained the same from birth. Abnormal hypotonia and developmental delay were evident during the examination. Figure 1 illustrates a picture of our patient at 27 months old. Her parents first noticed hypotonia at 2 months of age, and she failed to reach the developmental milestones within the expected timeline. She was unable to maintain head control without support until the age of 7 months. She gradually gained the ability to sit with support after 12 months. By the age of 24 months, she could roll over, stand with support, and uttered a few incomprehensible sounds. A picture of our patient with Griscelli type 1 syndrome without the classic silvery hair, taken at 27 months of age. On the right side, the picture illustrates the abnormal melanin distribution of our patient’s hair under light microscope. This abnormal pattern has heterogenous pigmentation in both a part of a single strand or adjacent hair strands, deposition of nonuniform melanin along the cortex, and presence of unevenly scattered clumps of melanin granules. The granular pattern is heterogeneous along the cortex, with areas of fine (<2 µm) and coarse (>4 µm) aggregation. She had no visual impairment or any episodes of seizures up to the age of 27 months. Growth parameters were within the normal limits. At 1 year of age, she was evaluated for anemia, and a diagnosis of minor thalassemia was considered. At 24 months, a comprehensive evaluation for neurometabolic disorders was performed to determine the probable cause of the developmental delay. The immunological investigations showed no immunological or cytotoxic defects. Whole‐exome sequencing revealed a novel MYO5A mutation (c.3508C >T). This mutation occurs on exon 26 out of 42 of this gene and result in a premature stop codon that may produce a truncated protein. This variant is a likely pathogenic mutation according to The American College of Medical Genetics and Genomics (ACMG) guideline; it is a null variant and a loss of function mutation, which is a known mechanism of disease in this gene (PVS1). Additionally, this variant has an extremely low frequency in different databases like 1000 Genome and gnomAD (PM2). Considering the probable diagnosis of GS, her hair was further examined, which revealed an abnormal melanin distribution (Figure 1). Both parents were found to be heterozygous carriers of the MYO5A (c.3508C >T) mutation. GS1, as an autosomal recessive disorder, carries a 25% recurrence risk in future pregnancies for consanguineous couples. Genetic counseling was provided to the family, including discussing prenatal and preimplantation genetic diagnosis options. 3. Conclusion In this report, we present a 27‐month‐old child with hypotonia and neurodevelopmental delay as the main manifestations. Unlike the typical cases of GS, our patient did not initially display albinism or silver hair, which delayed the diagnosis of a melanocytic disorder. Only after genetic testing, a novel MYO5A mutation (c.3508C >T, p.Gln1170 ∗) was revealed. Later, the microscopic examination of her hair confirmed an abnormal melanin distribution, and the diagnosis of GS1 was established. This is the first reported case of GS1 presenting without the characteristic silver hair or pale bronze skin, only with a mild abnormality in melanocyte distribution. The MYO5A gene encodes a protein of the myosin family, which plays a crucial role in intracellular transport. Myosin proteins are also involved in maintaining cellular structure and facilitating overall cell movement through interactions with actin filaments [5], thus explaining the severe hypotonia in GS1 patients. In melanocytes, these functions are particularly important, as pigmentation relies on melanosomes, the intracellular organelles that contain melanin [6]. MYO5A interacts with proteins encoded by the RAB27A and MLPH genes to transport melanosomes within melanocytes. Disruption of this protein complex leads to pigmentation abnormalities, which are observed in all types of GS [7]. However, the MYO5A mutation (c.3508C >T, p.Gln1170 ∗) in our patient represents a previously unreported variant and may explain the milder pigmentation phenotype in our patient. MYO5A also plays a critical role in the nervous system. The intracellular movement of organelles within neurons, as well as their exocytosis, depends on functional myosin 5A. Therefore, mutations in MYO5A can result in severe neurological dysfunction [8], which is in line with the developmental delay in our case. In 1979, Elejalde described a syndrome characterized by skin and hair pigmentation abnormalities accompanied by profound neurological impairment and normal immune function [9]. Subsequent studies identified mutations at the 15q21 locus, which were later linked to MYO5A, leading to the reclassification of these patients as GS1 [10]. Interestingly, Cetica et al. [11] also reported GS2 patients with familial HLH and biallelic mutations in RAB27A in the absence of albinism. Their gene sequencing later revealed mutations that only disrupted the role of Rab27a in cytotoxic immunity [11]. This study illustrates the clinical variability of GS1 and underscores the importance of genetic testing in children with unexplained developmental delay and hypotonia. Our patient showed that GS1 may present with microscopic pigmentary abnormality. In such cases, genetic testing is essential to confirm the diagnosis. Identification of new mutations, such as our novel MYO5A mutation, expands the mutational spectrum of GS1 and also genotype–phenotype correlations, resulting in an earlier diagnosis and better management. Nomenclature Griscelli syndrome GS type 1 Hemophagocytic lymphohistiocytosis Hematopoietic stem cell transplantation The American College of Medical Genetics and Genomics. Author Contributions Davoud AmirKashani performed analysis and interpreted the patient data, Soudabeh Hosseini assisted in patient diagnosis, Marziyeh Mojbafan performed genetical assessment of the patient, Niusha Sharifinejad contributed in manuscript writing and data gathering, and Sima Bahrami was a major contributor in interpretation of patient data and writing the manuscript. Funding No funding was received for this manuscript. Disclosure All authors have read and approved the final manuscript. Ethics Statement The authors have nothing to report. Consent Informed consent was obtained from the parents of the patient prior to being included in the study. Conflicts of Interest The authors declare no conflicts of interest.